By Cara Murez
WEDNESDAY, Nov. 4, 2020 (HealthDay Information) — A brand new immunotherapy that has proven success towards multiple sclerosis in animals could possibly be promising for people, a brand new examine suggests.
Researchers at Thomas Jefferson College in Philadelphia are learning a drug that may stop immune system cells from attacking the myelin sheath, a protecting layer that surrounds nerve cells. With MS, the physique’s immune system assaults the central nervous system by attacking the myelin sheath.
Whereas this remedy would impede the autoimmune response, it could depart the remainder of the immune system totally functioning, based on the examine.
“This can be a large benefit of our antigen-specific methodology over present therapies, that are like a sledgehammer to the immune system,” mentioned senior examine writer Dr. Abdolmohamad Rostami, chairman of the Division of Neurology at Sidney Kimmel Medical School at Thomas Jefferson College.
“There are various attainable immune-activating antigens within the myelin sheath, however the largest hurdle is that we do not know which part of myelin is triggering the immune response in MS sufferers,” Rostami defined. “Earlier research have used single myelin antigens or combos of antigens to stop autoimmunity in animal fashions, however in people they’ve had restricted success.”
For this examine, researchers checked out cells known as oligodendrocytes, which wrap their cell membrane round nerve cells to provide the myelin sheath. Scientists can harvest tiny sacs known as extracellular vesicles (EVs) from these cultured cells. Researchers consider these EVs include all of the related myelin antigens, which implies there could be a better likelihood they may cease the autoimmune assault on myelin.
“The neat factor about these EVs is that they provide us a chance to deal with the illness in an antigen-specific approach, with out having to know the precise identification of the goal antigen,” Rostami mentioned in a college information launch. “It covers all of the bases.”
Researchers injected these EVs into three completely different mouse fashions meant to point out impression on MS at each early and late levels. They reported that it prevented onset of signs like decreased mobility and paralysis when administered earlier than the illness developed, in addition to decreasing severity of illness when given later.
That this strategy was efficient in several fashions suggests this might act as a common remedy, Rostami famous. Nevertheless, outcomes from animal research don’t all the time pan out in people.
The researchers mentioned they have been additionally in a position to isolate EVs from human cells, discovering in addition they contained a number of myelin antigens. It is attainable that they may have the identical therapeutic impact in sufferers, based on the examine.
Rostami and his staff are engaged on patenting the intravenous EVs strategy.
The examine was printed Nov. 4 in Science Translational Medication.
Go to the Nationwide A number of Sclerosis Society to study extra about treatments for MS.
SOURCE: Thomas Jefferson College, information launch, Nov. 3, 2020